Results CALENDAR
W
T
F
S
S
M
T
W
T
F
S
S
M
T
W
T
F
S
S
M
T
W
T
F
S
S
M
T
W
T
F
May 2013 12345678910111213141516171819202122232425262728293031
India Earnings >> Pre Result Estimates
You are here : Home » Pre Result Estimates
Pharmaceuticals Sector
 
 Pre Result Estimates
12345678910Next
Lupin Q4: Analysts expect 108% PAT growth at Rs 324 cr       8th-May-2013
Healthcare firm Lupin will announce its fourth quarter (January-March) earnings on Wednesday. Analysts on an average expect the profit after tax to grow by 108.3 percent year-on-year to Rs 324 crore, according to CNBC-TV18 poll.
Ranbaxy Q1 profit likely at Rs 173cr; revenue seen down 31%       8th-May-2013
Ranbaxy's first quarter net profit is seen at Rs 173 crore, compared with a Rs 1,246 crore profit in the year ago quarter, according to a CNBC-TV18 poll. The results are not really comparable since it got a boost from launch of generic Lipitor last year.
Glenmark Q4 net profit seen flat at Rs 150cr         7th-May-2013
Glenmark Pharma is likely to report 16 percent year-on-year growth in fourth quarter revenue at Rs 1,240 crore, whilenet profit is seen flat at Rs 150 crore, according to a CNBC-TV18 poll.
Biocon Q4: Analysts expect 9% drop in PAT to Rs 89.4cr       23rd-Apr-2013
Pharmaceutical firm Biocon is set to declare its fourth quarter FY13 numbers on Thursday. Analysts on an average expect the company's profit after tax to fall by 9 percent year-on-year to Rs 89.4 crore due to lower operational performance, according to
IIFL gung-ho on pharma, expects Sun to beat Q4 estimates         18th-Apr-2013
Bino Pathiparampil of IIFL, says that stock like Sun Pharma has been beating estimates for last eight quarters and the same performance is likely to continue in this quarter. Ranbaxy’s business has been worsening over the last 2-3 quarters and one can’t
Pharma cos likely to post 21% EBITDA growth in Q4: MOST       16th-Apr-2013
Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).
Dr Reddy's Q3 revenue seen up 5% at Rs 2,913cr       13th-Feb-2013
Strong growth in US generic drug sales will continue to drive revenue growth for Dr Reddy's Laboratories. The pharma major will report its third quarter earnings on Thursday.
Cadila Healthcare Q3 profit seen up 31% to Rs 195 cr       8th-Feb-2013
Cadila Healthcare is set to declare its third quarter numbers on Friday. Analysts on an average expect profit after tax of the company to grow by 31 percent year-on-year to Rs 195 crore in the quarter, according to CNBC-TV18 poll.
Sun Pharma Q3 net seen up 25% to Rs 838cr on Taro, Lipodox         8th-Feb-2013
Healthcare firm Sun Pharmaceutical is set to announce its third quarter results on Friday. Analysts on an average were expecting profit after tax to grow by 25 percent year-on-year to Rs 838 crore in the quarter, helped by Taro numbers and Lipodox generic.
Cipla Q3: Analysts expect Q3 profit to grow 38% at Rs 372cr         6th-Feb-2013
Healthcare firm Cipla is set to announce its results for the third quarter of financial year 2012-13 on Wednesday. Analysts on an average expect the company to report good numbers year-on-year due to overall operational improvement.
Lupin Q3: Analysts expect profit to grow 27% to Rs 299 cr         31st-Jan-2013
Healthcare firm Lupin is set to declare its results for the third quarter of financial year 2012-13 on Thursday. Analysts on an average expect profit after tax of the company to grow by 27 percent year-on-year to Rs 299 crore in the quarter.
Glenmark Pharma Q3 profit seen up 4 times to Rs 181 cr         29th-Jan-2013
Glenmark Pharma is set to declare its results for the third quarter of financial year 2012-13 on Tuesday. Analysts on an average expect profit after tax to grow 4 times year-on-year to Rs 181 crore in the quarter due to EBITDA expansion and one off income.
Biocon Q3: Analysts expect PAT growing 6% to Rs 90 cr       24th-Jan-2013
Healthcare firm Biocon is set to declare its third quarter results on Thursday. Analysts on an average expect profit after tax of the company to grow by 6 percent year-on-year to Rs 89.6 crore in the quarter.
Good performance likely from pharma in Q3: Nirmal Bang       12th-Jan-2013
Nirmal Bang has come out with its earnings estimates for pharmaceutical sector for the quarter ended December 2012. The research firm feels margins of pharma companies may witness YoY expansion owing to rupee depreciation (6 percent YoY).
See pharma sector's Q3 topline to grow 22%: Motilal Oswal       12th-Jan-2013
Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy,

Results so Far

Search

 Best Performers
 Worst Performers
 Positive Turnarounds
 Negative Turnarounds
 Latest Results
 Sector Performance
Most Visited
 Results Calendar
 Board Meetings
 Book Closures
 Dividend Calendar
 Brokerage Reports
 FII Comments
 Pre Result Estimates
 Results At A Glance
 Interview With Management
 CNBC TV18 Live Video
Results at a glance
State Bank of India Q4 net falls 18... May 23
Jyothy Labs Q4 net plunges 57% to R... May 22
Voltas consolidated Mar '13 sales a... May 22
more
Press Releases
Pre Result Estimates
Factors that will impact JSW Steel'... May 23
Here's what to expect from SBI Q4 e... May 22
Will Europe operations dent Tata St... May 22
more
Management Talk
Will sustain 10-15% growth in FY14:... May 23 Watch Video
Expect margins to remain at 25% lev... May 22 Watch Video
Rs 6000/sqft realisations sustainab... May 22 Watch Video
more
FII Comments
more
Analyst View
L&T likely to post 15-17% EPS growt... May 23 Watch Video
Buy L&T; skeptical on order inflow ... May 22 Watch Video
Bullish on L&T; FY14 topline growth... May 22 Watch Video
more
CNBC TV18 View
Indian pharmas gain on N America bo... May 09 Watch Video
HDFC Bank Q4 NII seen up 17% to Rs ... Apr 23 Watch Video
more
Brokerage Reports
Buy Tech Mahindra; target of Rs 121... May 23
Buy Tech Mahindra; target of Rs 117... May 23
Buy Birla Corporation; target of Rs... May 23
more
Press Conferences
Dip in Q4 net fails to dent L&T's m... May 22 Watch Video
Excise duty, higher input costs hur... May 21 Watch Video
We will refocus on growth in 2013-1... May 13 Watch Video
more
Analyst Concalls
more
Source : Dion Global Solutions Limited
Site Map  |  About us  |  Contact us  |  Advertise  |  Feedback  |  Disclaimer  |  Privacy Policy  |  Terms of Use
copyright © 2008. IndiaEarnings.com
Results
Results Till Now
Press Releases
Estimates
CEO CALL
Mgmt Interviews
Press Conference
Conference Calls
 
ANALYSIS
CNBC-TV18 View
Brokerage Calls
Analyst Views
NEWS